NASDAQ:ANAB - AnaptysBio Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $35.86
  • Forecasted Upside: 39.25 %
  • Number of Analysts: 7
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.06 (-0.23%)

This chart shows the closing price for ANAB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AnaptysBio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ANAB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ANAB

Analyst Price Target is $35.86
▲ +39.25% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for AnaptysBio in the last 3 months. The average price target is $35.86, with a high forecast of $43.00 and a low forecast of $29.00. The average price target represents a 39.25% upside from the last price of $25.75.

This chart shows the closing price for ANAB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 7 contributing investment analysts is to hold stock in AnaptysBio. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/22/2021HC WainwrightInitiated CoverageBuy$43.00High
5/20/2021UBS GroupInitiated CoverageNeutral$29.00Low
3/16/2021Truist SecuritiesUpgradeHold ➝ Buy$27.00 ➝ $34.00Low
3/16/2021TruistUpgradeHold ➝ Buy$27.00 ➝ $34.00Medium
3/15/2021WedbushReiterated RatingOutperform ➝ NeutralN/A
3/9/2021WedbushDowngradeOutperform ➝ NeutralMedium
3/8/2021JPMorgan Chase & Co.DowngradeOverweight ➝ UnderweightHigh
2/11/2021JPMorgan Chase & Co.UpgradeUnderweight ➝ Overweight$19.00 ➝ $40.00Low
10/27/2020TruistBoost Price Target$20.00 ➝ $27.00High
10/27/2020WedbushUpgradeNeutral ➝ Outperform$20.00 ➝ $35.00High
10/14/2020TruistBoost Price Target$16.00 ➝ $20.00High
10/14/2020GuggenheimUpgradeNeutral ➝ Buy$36.00High
5/7/2020Credit Suisse GroupBoost Price TargetNeutral$14.00 ➝ $16.00High
5/6/2020Stifel NicolausReiterated RatingHold$17.00Low
3/3/2020SunTrust BanksLower Price TargetHold$15.00 ➝ $14.00High
3/2/2020Stifel NicolausReiterated RatingHold$18.00Low
11/8/2019Jefferies Financial GroupDowngradeBuy ➝ Hold$12.00N/A
11/8/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Underweight$109.00 ➝ $17.00N/A
11/8/2019WedbushDowngradeOutperform ➝ NeutralN/A
11/8/2019GuggenheimDowngradeBuy ➝ NeutralN/A
11/8/2019SunTrust BanksDowngradeBuy ➝ HoldN/A
10/3/2019Credit Suisse GroupLower Price TargetNeutral$75.00 ➝ $48.00Low
10/1/2019WedbushReiterated RatingOutperformHigh
9/30/2019Stifel NicolausReiterated RatingHoldHigh
8/20/2019Cantor FitzgeraldSet Price TargetBuy$140.00High
8/12/2019Stifel NicolausSet Price TargetHold$63.00Medium
8/9/2019Credit Suisse GroupLower Price TargetNeutral$79.00 ➝ $75.00High
6/24/2019HC WainwrightSet Price TargetBuy$126.00High
6/24/2019SunTrust BanksLower Price TargetBuy$125.00 ➝ $93.00High
6/21/2019Stifel NicolausDowngradeBuy ➝ Hold$124.00 ➝ $74.00High
6/21/2019Credit Suisse GroupDowngradeOutperform ➝ Neutral$137.00 ➝ $79.00High
5/8/2019Stifel NicolausSet Price TargetBuy$124.00High
4/2/2019Cantor FitzgeraldSet Price TargetBuy$140.00High
4/2/2019Stifel NicolausSet Price TargetBuy$124.00High
3/26/2019Cantor FitzgeraldReiterated RatingBuy$140.00High
3/1/2019WedbushReiterated RatingOutperformMedium
2/27/2019Cantor FitzgeraldReiterated RatingBuy$140.00Low
2/22/2019GuggenheimInitiated CoverageBuy$135.00High
1/18/2019SunTrust BanksLower Price TargetBuy$125.00Medium
12/20/2018HC WainwrightInitiated CoverageBuy ➝ Buy$126.00High
12/3/2018Cantor FitzgeraldSet Price TargetBuy$140.00Medium
11/21/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$115.00High
11/11/2018Stifel NicolausSet Price TargetBuy$127.00Medium
11/9/2018Credit Suisse GroupSet Price TargetBuy$143.00N/A
11/9/2018Cantor FitzgeraldSet Price TargetBuy$140.00N/A
10/16/2018Cantor FitzgeraldReiterated RatingBuy$140.00High
9/27/2018Credit Suisse GroupSet Price TargetOutperform ➝ Buy$104.00 ➝ $147.00Low
9/22/2018Cantor FitzgeraldSet Price TargetBuy$124.00High
9/18/2018WedbushReiterated RatingOutperform$138.00Low
9/16/2018Cantor FitzgeraldSet Price TargetBuy$124.00High
9/14/2018Stifel NicolausSet Price TargetBuy$127.00Low
9/4/2018Cantor FitzgeraldInitiated CoverageBuy$124.00Low
8/27/2018Cantor FitzgeraldInitiated CoverageOverweight$124.00Medium
8/15/2018JMP SecuritiesLower Price TargetMarket Outperform ➝ Buy$180.00 ➝ $153.00Low
8/8/2018Royal Bank of CanadaReiterated RatingHold$84.00Low
8/7/2018Jefferies Financial GroupReiterated RatingBuy$121.00Low
7/19/2018Credit Suisse GroupInitiated CoverageOutperform$104.00High
4/4/2018Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$144.00 ➝ $40.00High
3/27/2018JMP SecuritiesSet Price TargetBuy$180.00Low
3/27/2018WedbushReiterated RatingOutperform$151.00High
3/26/2018Stifel NicolausSet Price TargetBuy ➝ Buy$139.00 ➝ $152.00High
3/6/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$130.00 ➝ $139.00Medium
3/2/2018Royal Bank of CanadaBoost Price TargetOutperform$144.00Low
2/20/2018WedbushReiterated RatingOutperform ➝ Outperform$142.00High
2/19/2018Jefferies Financial GroupBoost Price TargetBuy$6.59 ➝ $145.00High
2/15/2018SunTrust BanksBoost Price TargetBuy ➝ Buy$115.00 ➝ $162.00Low
1/23/2018Credit Suisse GroupSet Price TargetOutperform ➝ Outperform$85.00 ➝ $135.00Medium
1/19/2018Robert W. BairdReiterated RatingBuy$81.00 ➝ $144.00High
12/18/2017Royal Bank of CanadaBoost Price TargetOutperform$108.00Medium
11/15/2017SunTrust BanksInitiated CoverageBuy ➝ Buy$115.00N/A
11/9/2017Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$101.00N/A
11/7/2017WedbushReiterated RatingOutperform ➝ Positive$75.00 ➝ $82.00N/A
10/13/2017Stifel NicolausReiterated RatingBuy$35.00 ➝ $76.00N/A
10/13/2017WedbushReiterated RatingOutperform$37.00 ➝ $75.00N/A
10/11/2017Robert W. BairdSet Price TargetOutperform ➝ Buy$36.00 ➝ $69.00N/A
10/10/2017Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$40.00 ➝ $79.00N/A
10/10/2017Credit Suisse GroupBoost Price TargetOutperform$38.00 ➝ $85.00N/A
10/10/2017JMP SecuritiesBoost Price TargetOutperform$45.00 ➝ $82.00N/A
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$40.00High
9/12/2017Stifel NicolausReiterated RatingBuy$35.00Low
8/25/2017Credit Suisse GroupBoost Price TargetOutperform$34.00 ➝ $38.00High
7/10/2017Robert W. BairdInitiated CoverageOutperform ➝ Outperform$36.00High
5/2/2017Stifel NicolausBoost Price TargetBuy$30.00 ➝ $35.00Low
4/18/2017Credit Suisse GroupReiterated RatingOutperform$34.00Medium
3/31/2017JMP SecuritiesReiterated RatingOutperform$45.00High
3/29/2017WedbushLower Price TargetOutperform$33.00 ➝ $28.00High
3/6/2017WedbushReiterated RatingOutperform$28.00N/A
2/21/2017WedbushInitiated CoverageOutperform ➝ Outperform$28.00N/A
2/21/2017Stifel NicolausInitiated CoverageBuy ➝ Buy$30.00N/A
2/21/2017Credit Suisse GroupInitiated CoverageOutperform ➝ OutperformN/A
2/21/2017JMP SecuritiesInitiated CoverageMkt Outperform ➝ OutperformN/A
(Data available from 7/25/2016 forward)
AnaptysBio logo
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Imsidolimab, an IL-36R antibody that inhibits the interleukin-36 receptor for the treatment of various dermatological inflammatory diseases; ANB030, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. It also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. AnaptysBio, Inc. has a collaboration and license agreement with TESARO, Inc. and Celgene Corporation; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $25.75
Low: $25.18
High: $26.00

50 Day Range

MA: $25.04
Low: $22.80
High: $26.44

52 Week Range

Now: $25.75
Low: $13.92
High: $35.85


108,015 shs

Average Volume

222,784 shs

Market Capitalization

$704.78 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of AnaptysBio?

The following Wall Street research analysts have issued stock ratings on AnaptysBio in the last twelve months: Guggenheim, HC Wainwright, JPMorgan Chase & Co., Truist, Truist Securities, UBS Group AG, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for ANAB.

What is the current price target for AnaptysBio?

7 Wall Street analysts have set twelve-month price targets for AnaptysBio in the last year. Their average twelve-month price target is $35.86, suggesting a possible upside of 39.3%. HC Wainwright has the highest price target set, predicting ANAB will reach $43.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $29.00 for AnaptysBio in the next year.
View the latest price targets for ANAB.

What is the current consensus analyst rating for AnaptysBio?

AnaptysBio currently has 1 sell rating, 2 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ANAB, but not buy more shares or sell existing shares.
View the latest ratings for ANAB.

What other companies compete with AnaptysBio?

How do I contact AnaptysBio's investor relations team?

AnaptysBio's physical mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company's listed phone number is 858-362-6295 and its investor relations email address is [email protected] The official website for AnaptysBio is